Puma Biotechnology Inc (PBYI)

80.00
0.70 0.87
NASDAQ : Health Care
Prev Close 80.70
Open 80.05
Day Low/High 79.10 / 81.05
52 Wk Low/High 28.35 / 98.85
Volume 551.91K
Avg Volume 1.66M
Exchange NASDAQ
Shares Outstanding 37.21M
Market Cap 3.06B
EPS -8.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Jim Cramer is bullish on Philip Morris, 3M and Becton Dickinson; but he's bearish on Blue Apron and Puma Biotechnology.

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Jim Cramer says history doesn't have to repeat itself. You don't want to miss another opportunity in the highly visible FANG-style stocks.

Puma Biotechnology Receives Day-180 List Of Outstanding Issues From Committee For Medicinal Products For Human Use (CHMP)

Puma Biotechnology Receives Day-180 List Of Outstanding Issues From Committee For Medicinal Products For Human Use (CHMP)

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has issued its Day-180 List of Outstanding...

Puma Announces Availability Of NERLYNX™ (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In The United States

Puma Announces Availability Of NERLYNX™ (neratinib) For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer In The United States

Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that NERLYNX™ (neratinib) tablets, formerly known as PB272, is now commercially available by prescription in the United States.

5 New Breast Cancer Treatments That Are Helping to Save Lives

5 New Breast Cancer Treatments That Are Helping to Save Lives

In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Up as Breast Cancer Program Gets Green Light; Nektar's Oxycodon Comp. Gets Praise

Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.

Puma Biotechnology Completes Targeted Enrollment In Neratinib Phase III Metastatic Breast Cancer Trial

Puma Biotechnology Completes Targeted Enrollment In Neratinib Phase III Metastatic Breast Cancer Trial

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that targeted patient enrollment in the Phase III NALA trial of the Company's lead drug candidate PB272 (neratinib) in patients with...

PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. to Contact The Firm

PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. to Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc.

The Klein Law Firm Reminds Investors Of A Class Action Filed On Behalf Of Puma Biotechnology, Inc. Shareholders And A Lead Plaintiff Deadline Of July 7, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc.

The Klein Law Firm Announces A Class Action Filed On Behalf Of Puma Biotechnology, Inc. Shareholders And A Lead Plaintiff Deadline Of July 7, 2017

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc.

PBYI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Puma Biotechnology, Inc. And A Lead Plaintiff Deadline Of July 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Puma Biotechnology, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc.

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.

Puma Biotechnology Announces Positive PB272 Phase II Data From TBCRC 022 Trial In Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases At The 2017 ASCO Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial (Translational Breast Cancer Research Consortium TBCRC 022) of...

PBYI INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Puma Biotechnology, Inc. And A Lead Plaintiff Deadline Of July 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc.

Puma Biotechnology To Present At The Jefferies 2017 Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc.

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Aerie Pharmaceuticals, BioCryst Pharmaceuticals and GW Pharmaceuticals were among the biotech movers in premarket trading on Thursday.

Puma Biotechnology Receives FDA Advisory Committee Support For Neratinib

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that the U.

This Market is Now Overbought; Waiting for Another Pullback

This Market is Now Overbought; Waiting for Another Pullback

Despite the good action in the indices, I'm not putting much money to work.

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.